Last reviewed · How we verify
Cyclophosphamide and glucocorticoids
Cyclophosphamide is an alkylating agent that damages DNA and suppresses immune cell proliferation, while glucocorticoids reduce inflammation and immune activation.
Cyclophosphamide is an alkylating agent that damages DNA and suppresses immune cell proliferation, while glucocorticoids reduce inflammation and immune activation. Used for Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis), Hematologic malignancies, Severe immune-mediated conditions refractory to other therapies.
At a glance
| Generic name | Cyclophosphamide and glucocorticoids |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Alkylating agent + corticosteroid combination |
| Modality | Small molecule |
| Therapeutic area | Immunology, Hematology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA, leading to cell death in rapidly dividing cells including malignant and immune cells. Glucocorticoids enhance this effect by suppressing T-cell and B-cell function and reducing inflammatory cytokine production. This combination is used to treat autoimmune and hematologic conditions where aggressive immunosuppression is needed.
Approved indications
- Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis)
- Hematologic malignancies
- Severe immune-mediated conditions refractory to other therapies
Common side effects
- Myelosuppression (leukopenia, thrombocytopenia)
- Infection
- Hemorrhagic cystitis
- Nausea and vomiting
- Alopecia
- Secondary malignancy
- Infertility
- Immunosuppression-related complications
Key clinical trials
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) (PHASE2)
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) (PHASE3)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study) (PHASE3)
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL (PHASE2)
- Rescue of Nephrons With ALE.F02 (RENAL-F02) (PHASE2)
- ALL Backbone in AYAs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: